Orciprenaline
生产企业：Boehringer ingelheim pharmaceuticals inc, Astrazeneca lp，另有 14 家
Orciprenaline is a beta-2 adrenergic agonist used to treat bronchospasm, asthma, and COPD.
Orciprenaline is a beta-2 adrenergic agonist used to treat bronchospasm, asthma, and COPD.
Orciprenaline stimulates the β2-adrenergic receptor expressed in the lungs, uterus, and vasculature supplying skeletal muscles by acting as a moderately selective agonist. It exerts minimal or no effect on alpha-adrenergic receptors. Intracellularly, the actions of orciprenaline are mediated by cAMP, the production of which is augmented by beta stimulation. The drug is believed to work by activating adenylate cyclase, the enzyme responsible for producing the cellular mediator cAMP.
用于支气管哮喘和哮喘型支气管炎、慢性阻塞性肺病所致支气管痉挛。亦可静脉滴注用于房室传导阻滞。
每项发明一条，涵盖美国、欧洲、PCT 与中国的同族专利。
未检索到以该名称命名的专利
专利文献通常使用化学名或研发代号指代药物，而非通用名；且专利申请在提交约 18 个月后才公开，较新的药物可能尚未出现在这里。
